ArticleJournal of cheminformatics2025
Prediction of UGT-mediated phase II metabolism via ligand- and structure-based predictive models.
Article in Journal of cheminformatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Machine-Learning-Driven Optimization of Functional Excipients and Their Biointeractions in Drug Formulations.ACS pharmacology & translational science · 2026Review
- Phase I Metabolism of Novel Phencyclidine Derivative 3-Cl-PCP: In Vitro Studies With Pooled Human Liver Microsomes and Investigation of a Post-Mortem Case.Drug testing and analysis · 2026Article
- Advances in UDP-Glycosyltransferases from Medicinal Plants: Discovery, Catalytic Mechanism, Engineering and Biosynthetic Application.Metabolites · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The prediction of drugs metabolism by in silico techniques is gaining a growing interest due to the possibility to process large datasets allowing the stability and safety of new drug candidates to be evaluated during the early stages of the drug discovery process. To date, in silico models for metabolism prediction mainly exploits the ligand-based (LB) properties of the training molecules to predict the occurrence of a given metabolic reaction and/or the reactive site involved in the biotransformation. However, recent reports highlighted that structure-based (SB) modeling can be conveniently integrated with LB methods for drug metabolism prediction purpose, with the advantages to predict if a given molecule can fit the enzyme active site and which moiety approaches the catalytic residues. Herein, we developed machine learning models for UDP-glucuronosyltransferase (UGT)-mediated metabolism by using both LB and SB methods. In particular, this study was focused on UGT2B7 and UGT2B15 isoforms which are involved in the clearance of many drugs as well as in clinically relevant drug-drug interactions. First, molecular dynamics (MD) and docking simulations were combined to explore the binding mechanism of cofactor and substrate within the catalytic pocket of the studied UGT isoforms exploiting their AlphaFold structures. The analysis of the MD trajectories allowed an appropriate conformation of both UGT isoforms to be identified for the development of binary classification models. For this purpose, Random Forest algorithm and the metabolic data extracted from the MetaQSAR database were used. SB models were trained on a set of scoring functions and protein-ligand interaction fingerprints derived from docking, while the LB models were built on a set of physicochemical and constitutional descriptors. When the single models were evaluated, the LB classifiers outperformed the SB models. However, the application of a consensus strategy led to an improvement of the prediction accuracy if compared to the individual models, highlighting that LB and SB approaches convey complementary information whose aggregation allowed us to achieve better predictions than the single models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.